Private equity firm Blackstone buys Japanese pharma Ayumi for reported $1 billion

Country : Japan, U.S.

Keywords :
LONDON, 15 Mar (APM) - U.S. private equity firm Blackstone Group said on Friday it has agreed to buy Japanese pharma Ayumi Pharmaceutical Corp in a deal reported valued at about $1 billion.
Blackstone will take control of the maker of anti-rheumatism drugs from PE firm Unison Capital and medical information site business M3, Blackstone said in a statement.
The acquisition marks Blackstone’s first private equity investment in Japan, with completion due in the second quarter.
It did not provide any details on the deal value. However, Thomson Reuters is reporting the deal's value at about $1 billion, according to a source.
"We look forward to working with the company to leverage Blackstone's global footprint and expertise in this sector to help Ayumi meet the growing need for its RA (rheumatoid arthritis) and orthopedic products," Atsuhiko Sakamoto, head of Blackstone's PE business in Japan, said in the statement.
Blackstone said Ayumi's flagship analgesic product, Calonal, is the market leading prescription acetaminophen drug with strong brand awareness among doctors, pharmacists, and patients in Japan.
"As a well-established product in the market, Calonal is a leading prescription of choice among physicians given its effective and safe treatment of chronic pain for patients across numerous disease areas," it said.



Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations

Events coverage with a unique focus on Market Access & sustainability of healthcare systems

6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris

Ask for a Free trial and get access to the latest stories

Our coverage includes:
  • Health Care
  • Market Access
  • HTA – policies & practices
  • European medicine regulations
  • Drug safety issues
  • Pricing & Reimbursement
  • International medicines agencies

If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.


an initial 10 day temporary access of APM Health Europe.